search
Back to results

Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery

Primary Purpose

Diabetes Mellitus Type 2, Insulin Resistance

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Intensified insulin therapy
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing elective colorectal surgery for non-metastatic disease
  • Type 2 diabetes mellitus with plasma level of glycosylated hemoglobin level (HbA(1c)) less than 10% indicating normal or moderate glycemic control
  • Being capable of signing informed consent
  • Accepting an epidural catheter for perioperative analgesia

Exclusion Criteria:

  • American Society of Anesthesiologists (ASA) Physical Status classification system 4 with major cardiac disorders (severe arrhythmias, recent myocardial ischemia (MI), heart failure, uncontrolled hypertension)
  • Hepatic disorders (liver failure, jaundice, metastatic disease), renal disorders (acute or chronic renal failure or on dialysis)
  • Metabolic disorders (untreated hyperthyroidism, pyrexia, more than 10% weight loss over the preceding three months, plasma albumin concentration < 35g/l)
  • Anemia (hemoglobin < 10 g/dl)
  • Chemotherapy or radiotherapy during six months before surgery
  • Inflammatory bowel disease or other inflammatory condition
  • Pregnancy
  • Previous spine surgery precluding placement of an epidural catheter.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Intensified insulin group

    Control group

    Arm Description

    Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.

    Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses

    Outcomes

    Primary Outcome Measures

    Postoperative protein balance (leucine) (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period

    Secondary Outcome Measures

    Intraoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
    Intraoperative protein metabolism: endogenous rate of appearance of leucine (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
    Intraoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
    Intraoperative glucose metabolism: Glucose clearance (ml/kg/min)
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement
    Postoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Postoperative protein metabolism: Endogenous rate of appearance of leucine (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Postoperative protein metabolism: Leucine oxidation (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Postoperative protein metabolism: Protein synthesis (leucine) (umol/kg/h)
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Postoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
    Postoperative glucose metabolism: Glucose clearance (ml/kg/min)
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement

    Full Information

    First Posted
    August 8, 2016
    Last Updated
    August 8, 2016
    Sponsor
    University Hospital, Basel, Switzerland
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02863276
    Brief Title
    Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery
    Official Title
    Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2009 (undefined)
    Primary Completion Date
    November 2010 (Actual)
    Study Completion Date
    November 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Basel, Switzerland

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Background Surgical injury provokes a stress response. These pathways mediated by stress hormones and cytokines cause a catabolic state. The loss of body cell mass may result in prolonged convalescence and increased morbidity. Protein catabolism after colorectal surgery is even more increased in patients with type 2 diabetes mellitus. Epidural blockade, by reducing the intensity of the catabolic response, improves substrate utilization after surgery in non-diabetic patients. This effect is even more pronounced in diabetic patients receiving amino acids. The aim of the study is to explore the effect of two different protocols to manage blood glucose control on glucose and protein metabolism in patients with type 2 diabetes mellitus undergoing colon surgery and receiving epidural analgesia and perioperative feeding with amino acids. The following hypotheses are tested: Tight perioperative blood glucose control with intensified insulin therapy compared to standard blood glucose control in presence of general anesthesia with epidural analgesia and amino acid infusion would reduce endogenous glucose production and leucine oxidation. Tight blood glucose control and perioperative infusion of amino acids induce a more positive protein balance compared to standard blood glucose control by better oxidative glucose utilization and redirecting amino acids from oxidative to synthetic pathways. Material and Methods A total of 20 patients with diabetes mellitus type 2 undergoing elective colorectal surgery will be admitted to the study. Patients will be randomly assigned to receive standard blood glucose control (blood glucose target <10 mmol*l-1; control group; cytotoxic T lymphocyte (CTL) group, n=8) or to receive tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1; intensified insulin group; II group, n=8). All patients will receive general anesthesia and an epidural catheter for perioperative analgesia. During surgery (intraoperative state) and immediately after surgery (postoperative state) when receiving an amino acid infusion protein and glucose kinetics will be assessed using a stable isotope technique with L-[1-13C]leucine and [6,6-2H2]glucose and circulating concentrations of glucose, glucagon, insulin and cortisol will be measured. The primary endpoints of the study will be protein balance. Sample size is set to ensure at least 80% power at a significance level of 0.05.
    Detailed Description
    see information below

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus Type 2, Insulin Resistance

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    18 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Intensified insulin group
    Arm Type
    Experimental
    Arm Description
    Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
    Arm Title
    Control group
    Arm Type
    No Intervention
    Arm Description
    Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
    Intervention Type
    Procedure
    Intervention Name(s)
    Intensified insulin therapy
    Other Intervention Name(s)
    continuous insulin infusion
    Primary Outcome Measure Information:
    Title
    Postoperative protein balance (leucine) (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Secondary Outcome Measure Information:
    Title
    Intraoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
    Time Frame
    Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
    Title
    Intraoperative protein metabolism: endogenous rate of appearance of leucine (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
    Time Frame
    Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
    Title
    Intraoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
    Time Frame
    Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
    Title
    Intraoperative glucose metabolism: Glucose clearance (ml/kg/min)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement
    Time Frame
    Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
    Title
    Postoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Title
    Postoperative protein metabolism: Endogenous rate of appearance of leucine (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Title
    Postoperative protein metabolism: Leucine oxidation (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Title
    Postoperative protein metabolism: Protein synthesis (leucine) (umol/kg/h)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Title
    Postoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
    Title
    Postoperative glucose metabolism: Glucose clearance (ml/kg/min)
    Description
    Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement
    Time Frame
    Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients undergoing elective colorectal surgery for non-metastatic disease Type 2 diabetes mellitus with plasma level of glycosylated hemoglobin level (HbA(1c)) less than 10% indicating normal or moderate glycemic control Being capable of signing informed consent Accepting an epidural catheter for perioperative analgesia Exclusion Criteria: American Society of Anesthesiologists (ASA) Physical Status classification system 4 with major cardiac disorders (severe arrhythmias, recent myocardial ischemia (MI), heart failure, uncontrolled hypertension) Hepatic disorders (liver failure, jaundice, metastatic disease), renal disorders (acute or chronic renal failure or on dialysis) Metabolic disorders (untreated hyperthyroidism, pyrexia, more than 10% weight loss over the preceding three months, plasma albumin concentration < 35g/l) Anemia (hemoglobin < 10 g/dl) Chemotherapy or radiotherapy during six months before surgery Inflammatory bowel disease or other inflammatory condition Pregnancy Previous spine surgery precluding placement of an epidural catheter.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Andrea Kopp Lugli, MD, MSc
    Organizational Affiliation
    University Hospital, Basel, Switzerland
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery

    We'll reach out to this number within 24 hrs